Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
12.96
-0.20 (-1.52%)
Nov 10, 2026, 12:07 PM EST - Market open
Pharming Group Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Pharming Group stock has a consensus rating of "Strong Buy" and an average price target of $35.1. The average 1-year stock price forecast is 170.83% higher than the current stock price, while the lowest is $23.4 (+80.56%) and the highest is $41 (+216.36%).
Price Target: $35.1 (+170.83%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Pharming Group stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $37 | Buy | Reiterates | $37 | +185.49% | Nov 6, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $38 → $41 | Buy | Maintains | $38 → $41 | +216.36% | Oct 29, 2026 |
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Maintains $39 | Buy | Maintains | $39 | +200.93% | Oct 28, 2026 |
Financial Forecast
Revenue This Year
387.34M
from 376.13M
Increased by 2.98%
Revenue Next Year
422.02M
from 387.34M
Increased by 8.95%
EPS This Year
0.03
from 0.00
Increased by 552.50%
EPS Next Year
0.04
from 0.03
Increased by 59.27%
EPS and Forward PE are based on non-GAAP adjusted numbers.